Prostaglandin E2 Alters the Differentiation and Function of Antigen-Specific T Cells By Targeting the Metabolic Gene Regulatory Network Downstream of mTORC1

Umbilical cord blood transplantation (UCBT) has extended the availability of hematopoietic stem cell transplantation to patients without compatible adult donors. Studies in zebrafish and mouse models have shown that the prostaglandin compound, 16,16 dimethyl prostaglandin E2 (PGE2), increases HSC nu...

Full description

Saved in:
Bibliographic Details
Published inBlood Vol. 128; no. 22; p. 552
Main Authors Herbel, Christoph, Patsoukis, Nikolaos, Weaver, Jessica D, Boussiotis, Vassiliki A.
Format Journal Article
LanguageEnglish
Published Elsevier Inc 02.12.2016
Online AccessGet full text

Cover

Loading…
Abstract Umbilical cord blood transplantation (UCBT) has extended the availability of hematopoietic stem cell transplantation to patients without compatible adult donors. Studies in zebrafish and mouse models have shown that the prostaglandin compound, 16,16 dimethyl prostaglandin E2 (PGE2), increases HSC number and homing. In a human clinical trial of double UCBT, PGE2 decreased time to engraftment, promoted early T cell chimerism, favored generation of long-lived memory CD8+ cells and reduced the incidence of CMV viremia. To obtain mechanistic insight of how PGE2 affects the differentiation program of antigen-specific T cells, we used a well-established model of T effector (TEFF) vs. T memory (TM) differentiation of TCR-transgenic OTI T cells. OTI cells were stimulated with Ova257-264 plus APC with or without PGE2, followed by incubation with either IL-2 or IL-7, which are critical for the development of CD8+ TEFF and TM, respectively. Antigen-specific stimulation with or without PGE2 followed by IL-2 resulted in differentiation to CD44+CD62L- TEFF cells. In contrast, antigen-specific stimulation followed by IL-7 resulted in generation of CD44+CD62L+ central memory T cells. Under these conditions, PGE2 treatment gave rise to a phenotype of CD44-CD62L+Bcl2+Sca1+ cells, consistent with T stem cell memory. Two key pathways regulated by AMPK and mTOR have a decisive role on TM differentiation. AMPK can promote the generation of TM cells. However, we found that PGE2 inhibited AMPK activation indicating that differentiation of TM by PGE2 is not mediated by AMPK. Because the mTORC1-specific inhibitor rapamycin can promote the generation of TM, we focused our studies on the effects of PGE2 on mTORC1. Two classes of direct downstream targets of mTORC1 have been well characterized. mTOR phosphorylates the ribosomal protein S6 kinases (S6K1/2) and the eukaryotic initiation factor 4E (eIF4E)-binding proteins (4E-BP1/2), both of which control specific steps in the initiation of cap-dependent translation. mTORC1 activation can stimulate glycolysis as well as lipid biosynthesis. This is achieved through the activation of a transcriptional program affecting metabolic gene targets of hypoxia inducible factor 1a (HIF1a) and sterol regulatory element-binding protein (SREBP1/2). HIF1a is regulated downstream of 4E-BP whereas SREBP is regulated downstream of S6K1. Although the mTORC1 inhibitor rapamycin can promote differentiation of TM and Treg cells, recent studies revealed that mTORC1, via its effects on lipid metabolism has a mandatory role on Treg differentiation. We found that PGE2 treatment during antigen-specific stimulation of OTI cells with Ova257-264 resulted in activation of mTOR as determined by phosphorylation of mTOR, 4E-BP and S6K and phosphorylation of Akt on the mTOR-specific site. Surprisingly, when antigen-specific stimulation was followed by IL-7, PGE2 treatment inhibited expression of the 4E-BP downstream targets Myc, HIF1a, the glycolysis genes Glut1, HK2, LDH-A, and the uptake of glucose. Phosphorylation of S6K was also impaired and lipid biosynthesis was suppressed as determined by decreased expression of fatty acid synthase FASN. In contrast, a metabolic program of lipid utilization was activated, characterized by increase of CPT1a, which promotes fatty acid transport in the mitochondria for b-oxidation, and the lipid oxidase Acox1. Mitochondria biogenesis analyzed by Mitotracker staining and expression of mitochondrial genes MTOC-1, TIMM50 and COX5a were also enhanced. In bioenergetics studies control-treated antigen-specific T cells had a glycolytic phenotype with elevated extracellular acidification rate (ECAR) whereas PGE2-treated cells had elevated oxygen consumption rate (OCR) and increased OCR/ECAR ratio, indicating preferential use of oxidative phosphorylation to generate energy. Thus, mTORC1 might regulate differentiation of antigen-specific T cells to TM by promoting lipid biosynthesis upon engaging distinct downstream targets in response to extracellular cues, thereby providing the required fuel for the bioenergetic demands of TM cells. Our studies reveal an unexpected mechanism by which PGE2 regulates the functional fate of T cells by modifying mTORC1 downstream signals and altering T cell metabolic imprints. These findings have implications for harnessing immune memory in the context of tumor-specific and pathogen-specific immunity. No relevant conflicts of interest to declare.
AbstractList Umbilical cord blood transplantation (UCBT) has extended the availability of hematopoietic stem cell transplantation to patients without compatible adult donors. Studies in zebrafish and mouse models have shown that the prostaglandin compound, 16,16 dimethyl prostaglandin E2 (PGE2), increases HSC number and homing. In a human clinical trial of double UCBT, PGE2 decreased time to engraftment, promoted early T cell chimerism, favored generation of long-lived memory CD8+ cells and reduced the incidence of CMV viremia. To obtain mechanistic insight of how PGE2 affects the differentiation program of antigen-specific T cells, we used a well-established model of T effector (TEFF) vs. T memory (TM) differentiation of TCR-transgenic OTI T cells. OTI cells were stimulated with Ova257-264 plus APC with or without PGE2, followed by incubation with either IL-2 or IL-7, which are critical for the development of CD8+ TEFF and TM, respectively. Antigen-specific stimulation with or without PGE2 followed by IL-2 resulted in differentiation to CD44+CD62L- TEFF cells. In contrast, antigen-specific stimulation followed by IL-7 resulted in generation of CD44+CD62L+ central memory T cells. Under these conditions, PGE2 treatment gave rise to a phenotype of CD44-CD62L+Bcl2+Sca1+ cells, consistent with T stem cell memory. Two key pathways regulated by AMPK and mTOR have a decisive role on TM differentiation. AMPK can promote the generation of TM cells. However, we found that PGE2 inhibited AMPK activation indicating that differentiation of TM by PGE2 is not mediated by AMPK. Because the mTORC1-specific inhibitor rapamycin can promote the generation of TM, we focused our studies on the effects of PGE2 on mTORC1. Two classes of direct downstream targets of mTORC1 have been well characterized. mTOR phosphorylates the ribosomal protein S6 kinases (S6K1/2) and the eukaryotic initiation factor 4E (eIF4E)-binding proteins (4E-BP1/2), both of which control specific steps in the initiation of cap-dependent translation. mTORC1 activation can stimulate glycolysis as well as lipid biosynthesis. This is achieved through the activation of a transcriptional program affecting metabolic gene targets of hypoxia inducible factor 1a (HIF1a) and sterol regulatory element-binding protein (SREBP1/2). HIF1a is regulated downstream of 4E-BP whereas SREBP is regulated downstream of S6K1. Although the mTORC1 inhibitor rapamycin can promote differentiation of TM and Treg cells, recent studies revealed that mTORC1, via its effects on lipid metabolism has a mandatory role on Treg differentiation. We found that PGE2 treatment during antigen-specific stimulation of OTI cells with Ova257-264 resulted in activation of mTOR as determined by phosphorylation of mTOR, 4E-BP and S6K and phosphorylation of Akt on the mTOR-specific site. Surprisingly, when antigen-specific stimulation was followed by IL-7, PGE2 treatment inhibited expression of the 4E-BP downstream targets Myc, HIF1a, the glycolysis genes Glut1, HK2, LDH-A, and the uptake of glucose. Phosphorylation of S6K was also impaired and lipid biosynthesis was suppressed as determined by decreased expression of fatty acid synthase FASN. In contrast, a metabolic program of lipid utilization was activated, characterized by increase of CPT1a, which promotes fatty acid transport in the mitochondria for b-oxidation, and the lipid oxidase Acox1. Mitochondria biogenesis analyzed by Mitotracker staining and expression of mitochondrial genes MTOC-1, TIMM50 and COX5a were also enhanced. In bioenergetics studies control-treated antigen-specific T cells had a glycolytic phenotype with elevated extracellular acidification rate (ECAR) whereas PGE2-treated cells had elevated oxygen consumption rate (OCR) and increased OCR/ECAR ratio, indicating preferential use of oxidative phosphorylation to generate energy. Thus, mTORC1 might regulate differentiation of antigen-specific T cells to TM by promoting lipid biosynthesis upon engaging distinct downstream targets in response to extracellular cues, thereby providing the required fuel for the bioenergetic demands of TM cells. Our studies reveal an unexpected mechanism by which PGE2 regulates the functional fate of T cells by modifying mTORC1 downstream signals and altering T cell metabolic imprints. These findings have implications for harnessing immune memory in the context of tumor-specific and pathogen-specific immunity. No relevant conflicts of interest to declare.
Abstract Umbilical cord blood transplantation (UCBT) has extended the availability of hematopoietic stem cell transplantation to patients without compatible adult donors. Studies in zebrafish and mouse models have shown that the prostaglandin compound, 16,16 dimethyl prostaglandin E2 (PGE2), increases HSC number and homing. In a human clinical trial of double UCBT, PGE2 decreased time to engraftment, promoted early T cell chimerism, favored generation of long-lived memory CD8+ cells and reduced the incidence of CMV viremia. To obtain mechanistic insight of how PGE2 affects the differentiation program of antigen-specific T cells, we used a well-established model of T effector (TEFF) vs. T memory (TM) differentiation of TCR-transgenic OTI T cells. OTI cells were stimulated with Ova257-264 plus APC with or without PGE2, followed by incubation with either IL-2 or IL-7, which are critical for the development of CD8+ TEFF and TM, respectively. Antigen-specific stimulation with or without PGE2 followed by IL-2 resulted in differentiation to CD44+CD62L- TEFF cells. In contrast, antigen-specific stimulation followed by IL-7 resulted in generation of CD44+CD62L+ central memory T cells. Under these conditions, PGE2 treatment gave rise to a phenotype of CD44-CD62L+Bcl2+Sca1+ cells, consistent with T stem cell memory. Two key pathways regulated by AMPK and mTOR have a decisive role on TM differentiation. AMPK can promote the generation of TM cells. However, we found that PGE2 inhibited AMPK activation indicating that differentiation of TM by PGE2 is not mediated by AMPK. Because the mTORC1-specific inhibitor rapamycin can promote the generation of TM, we focused our studies on the effects of PGE2 on mTORC1. Two classes of direct downstream targets of mTORC1 have been well characterized. mTOR phosphorylates the ribosomal protein S6 kinases (S6K1/2) and the eukaryotic initiation factor 4E (eIF4E)-binding proteins (4E-BP1/2), both of which control specific steps in the initiation of cap-dependent translation. mTORC1 activation can stimulate glycolysis as well as lipid biosynthesis. This is achieved through the activation of a transcriptional program affecting metabolic gene targets of hypoxia inducible factor 1a (HIF1a) and sterol regulatory element-binding protein (SREBP1/2). HIF1a is regulated downstream of 4E-BP whereas SREBP is regulated downstream of S6K1. Although the mTORC1 inhibitor rapamycin can promote differentiation of TM and Treg cells, recent studies revealed that mTORC1, via its effects on lipid metabolism has a mandatory role on Treg differentiation. We found that PGE2 treatment during antigen-specific stimulation of OTI cells with Ova257-264 resulted in activation of mTOR as determined by phosphorylation of mTOR, 4E-BP and S6K and phosphorylation of Akt on the mTOR-specific site. Surprisingly, when antigen-specific stimulation was followed by IL-7, PGE2 treatment inhibited expression of the 4E-BP downstream targets Myc, HIF1a, the glycolysis genes Glut1, HK2, LDH-A, and the uptake of glucose. Phosphorylation of S6K was also impaired and lipid biosynthesis was suppressed as determined by decreased expression of fatty acid synthase FASN. In contrast, a metabolic program of lipid utilization was activated, characterized by increase of CPT1a, which promotes fatty acid transport in the mitochondria for b-oxidation, and the lipid oxidase Acox1. Mitochondria biogenesis analyzed by Mitotracker staining and expression of mitochondrial genes MTOC-1, TIMM50 and COX5a were also enhanced. In bioenergetics studies control-treated antigen-specific T cells had a glycolytic phenotype with elevated extracellular acidification rate (ECAR) whereas PGE2-treated cells had elevated oxygen consumption rate (OCR) and increased OCR/ECAR ratio, indicating preferential use of oxidative phosphorylation to generate energy. Thus, mTORC1 might regulate differentiation of antigen-specific T cells to TM by promoting lipid biosynthesis upon engaging distinct downstream targets in response to extracellular cues, thereby providing the required fuel for the bioenergetic demands of TM cells. Our studies reveal an unexpected mechanism by which PGE2 regulates the functional fate of T cells by modifying mTORC1 downstream signals and altering T cell metabolic imprints. These findings have implications for harnessing immune memory in the context of tumor-specific and pathogen-specific immunity. Disclosures No relevant conflicts of interest to declare.
Author Weaver, Jessica D
Herbel, Christoph
Patsoukis, Nikolaos
Boussiotis, Vassiliki A.
Author_xml – sequence: 1
  givenname: Christoph
  surname: Herbel
  fullname: Herbel, Christoph
  organization: Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
– sequence: 2
  givenname: Nikolaos
  surname: Patsoukis
  fullname: Patsoukis, Nikolaos
  organization: Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
– sequence: 3
  givenname: Jessica D
  surname: Weaver
  fullname: Weaver, Jessica D
  organization: Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston, MA
– sequence: 4
  givenname: Vassiliki A.
  surname: Boussiotis
  fullname: Boussiotis, Vassiliki A.
  organization: Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
BookMark eNqFkE1OwzAQhS0EEuXnCEi-QIo9TZpkhUqhgAQUQWFrOfY4GFIb2QbUu3BY0pY9i6fRaN57Gn0HZNd5h4SccDbkvILTpvNeD184VEOAYVFstEMGvIAqYwzYLhkwxsZZXpd8nxzE-MYYz0dQDMjPQ_AxybaTTltHL4FOuoQh0vSK9MIagwFdsjJZ72jvobNPpzaLN3TSX1p02dMHKmusogs6xa6L9HxFFzK0mKxrN013mGTju95yhQ7pI7afnUw-rOg9pm8f3umF_3YxBZTLdfNyMX-c8iOyZ2QX8fhvHpLn2eViep3dzq9uppPbTHEGkHGFIzNicqxqnUOlVM1MZXJZFhIalusSq6ZkuiwKA1qasWxqWWMFelzWEqpmdEiKba_qYcSARnwEu5RhJTgTa8Rig1isEQsA0eNdq8-dbXPYP_dlMYioLDqF2gZUSWhv_2n4BXssiqc
ContentType Journal Article
Copyright 2016 American Society of Hematology
Copyright_xml – notice: 2016 American Society of Hematology
DBID 6I.
AAFTH
AAYXX
CITATION
DOI 10.1182/blood.V128.22.552.552
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
DatabaseTitle CrossRef
DatabaseTitleList
CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Biology
Anatomy & Physiology
EISSN 1528-0020
EndPage 552
ExternalDocumentID 10_1182_blood_V128_22_552_552
S0006497119305531
GroupedDBID ---
-~X
.55
1CY
23N
2WC
34G
39C
4.4
53G
5GY
5RE
5VS
6I.
6J9
AAEDW
AAFTH
AAXUO
ABOCM
ABVKL
ACGFO
ADBBV
AENEX
AFOSN
AHPSJ
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CS3
DIK
DU5
E3Z
EBS
EJD
EX3
F5P
FDB
FRP
GS5
GX1
IH2
K-O
KQ8
L7B
LSO
MJL
N9A
OK1
P2P
R.V
RHF
RHI
ROL
SJN
THE
TR2
TWZ
W2D
W8F
WH7
WOQ
WOW
X7M
YHG
YKV
ZA5
0R~
0SF
AALRI
AAYXX
ADVLN
AFETI
AITUG
AKRWK
AMRAJ
CITATION
H13
ID FETCH-LOGICAL-c1022-1ce3f30a6c9d428cc90f8f4a75a2b04d7e8b70d755f2daf6ab9a9e82d679a28b3
IEDL.DBID ABVKL
ISSN 0006-4971
IngestDate Thu Sep 12 19:57:12 EDT 2024
Fri Feb 23 02:36:46 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 22
Language English
License This article is made available under the Elsevier license.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c1022-1ce3f30a6c9d428cc90f8f4a75a2b04d7e8b70d755f2daf6ab9a9e82d679a28b3
OpenAccessLink https://www.sciencedirect.com/science/article/pii/S0006497119305531
PageCount 1
ParticipantIDs crossref_primary_10_1182_blood_V128_22_552_552
elsevier_sciencedirect_doi_10_1182_blood_V128_22_552_552
PublicationCentury 2000
PublicationDate 2016-12-02
PublicationDateYYYYMMDD 2016-12-02
PublicationDate_xml – month: 12
  year: 2016
  text: 2016-12-02
  day: 02
PublicationDecade 2010
PublicationTitle Blood
PublicationYear 2016
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
SSID ssj0014325
Score 2.25549
Snippet Umbilical cord blood transplantation (UCBT) has extended the availability of hematopoietic stem cell transplantation to patients without compatible adult...
Abstract Umbilical cord blood transplantation (UCBT) has extended the availability of hematopoietic stem cell transplantation to patients without compatible...
SourceID crossref
elsevier
SourceType Aggregation Database
Publisher
StartPage 552
Title Prostaglandin E2 Alters the Differentiation and Function of Antigen-Specific T Cells By Targeting the Metabolic Gene Regulatory Network Downstream of mTORC1
URI https://dx.doi.org/10.1182/blood.V128.22.552.552
Volume 128
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYhoY9LSTctTR9hDqU373plybKOXidL0nTTEjYhNyPrAQu73pBsD_tf8mMzkuXSQskhB4MfkjCe8cw30ow-Qr4aX96YO54wx_KEMWqSglORcK0RzfOsEc5XI88u8tMr9v2G3-yQqq-F8WmV0fZ3Nj1Y63hnFL_m6Hax8DW-6E6lGCMESTn3tdR7FNEv_p175eT6_MefxQSW0Y7IAINn3yEW8iCyHoXs8OE1GukhpUPOw_F_F_WX25nukzcRL0LZvdJbsmPbATkoW4yVV1v4BiGDM0yND8iLSX_2qup53Abk5Swunx-Qh1--xkMF2o5FCycUSr9Yfg-IAuE4UqVsOmEBtoEper1wsXZQ4hPUtiQw1ruFhjlUdrm8h8kW5iGfHL1gGGlmN6haS2ziN7WGy47ufn23hYsu6RyO_Zy2z3Ff-ZFX85-X1fgduZqezKvTJNIzJNqHiclY28xlqcq1NBjEaC1TVzimBFe0SZkRtmhEagTnjhrlctVIJW1BTS6kokWTvSe77bq1HwiMpeFCKCuZbJhJtXReh1C9uPT71YtDMuwlUt92u3DUIXopaB1EWHsR1pTWKD5_HJKil1v9jzrV6Cme7vrx-V0_kdeIpwKvUUo_k93N3W_7BTHLpjmKOnmEqP3s_BFeEeq5
link.rule.ids 315,783,787,27581,27936,27937,45675
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Li9swEBZLlnZ7KW22pdunDqU3J44sWdbR8W5Iu0laFu-yNyHrAYHEWXbTQ_5Lf2xHslxaKD30IPBDEsYzzHwjzehD6KPx5Y25Ywl1NE8oJSYpGOEJ0xrQPMsa7nw18nKVz6_pl1t2e4SqvhbGp1VG29_Z9GCt45Nx_Jvju_Xa1_iCOxV8AhAkZczXUh8DGuBsgI7L6c3l4tdmAs1IR2QAwbMfEAt5AFmPQ3b46AaM9IiQEWOh_d1F_eZ2Zs_Q04gXcdl90nN0ZNshOi1biJW3B_wJhwzOsDQ-RI-m_dVJ1fO4DdHjZdw-P0U_vvkaDxVoO9YtviC49JvlDxhQID6PVCn7TlgY-uAZeL1ws3O4hDegbUlgrHdrjWtc2c3mAU8PuA755OAFw0xLuwfV2kAXf6g1vuro7nf3B7zqks7xuV_T9jnuWz_ztv56VU1eoOvZRV3Nk0jPkGgfJiYTbTOXpSrXwkAQo7VIXeGo4kyRJqWG26LhqeGMOWKUy1UjlLAFMTkXihRN9hIN2l1rXyE8EYZxrqygoqEm1cJ5HQL1YsKfV8_P0KiXiLzrTuGQIXopiAwilF6EkhAJ4vPtDBW93OQf6iTBU_x76Ov_H_oBnczr5UIuPq8u36AngK0Cx1FK3qLB_v67fQf4Zd-8j_r5EwDf7K4
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prostaglandin+E2+Alters+the+Differentiation+and+Function+of+Antigen-Specific+T+Cells+By+Targeting+the+Metabolic+Gene+Regulatory+Network+Downstream+of+mTORC1&rft.jtitle=Blood&rft.au=Herbel%2C+Christoph&rft.au=Patsoukis%2C+Nikolaos&rft.au=Weaver%2C+Jessica+D&rft.au=Boussiotis%2C+Vassiliki+A.&rft.date=2016-12-02&rft.pub=Elsevier+Inc&rft.issn=0006-4971&rft.eissn=1528-0020&rft.volume=128&rft.issue=22&rft.spage=552&rft.epage=552&rft_id=info:doi/10.1182%2Fblood.V128.22.552.552&rft.externalDocID=S0006497119305531
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon